ReviewPathologie (Heidelberg, Germany)2026
[General anatomic and histopathological diagnostic aspects of hereditary tumor syndromes : The role of pathology].
Review in Pathologie (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the widely increasing implementation of modern next generation sequencing (NGS) technologies in routine molecular pathology practice, the fraction of cancers with a definite or probable hereditary background has been steadily increasing. Currently, it is assumed that 5-10% of all malignancies develop in the context of germline predisposition diseases. Not rarely, the diagnosis and recognition of cancer predisposition syndromes rely on distinctive histopathological and/or immunophenotypical findings that proved to be highly reliable and reproducible in uncovering hereditary neoplastic diseases that would otherwise have gone undetected by clinicians. This is especially true in patients with new mutations and, hence, negative family history. Examples of such neoplasms are the fumarate hydratase-deficient renal cell carcinoma (FH-RCC), succinate dehydrogenase-deficient RCC (SDH-RCC), and hereditary gastrointestinal stromal tumor (GIST) syndromes. Notably, many of these inherited cancer syndromes may present as unifocal lesions at advanced age of onset so that they are mostly misinterpreted as sporadic on clinical grounds. The availability of effective disease-specific specialized cancer screening and follow-up programs for several hereditary cancer syndromes underlines the importance of timely recognition of these disorders to enable enrollment of "at-risk individuals" in such programs for early detection and timely prevention/treatment of these mostly aggressive neoplasms. This review highlights and discusses the major clinicopathological, topographic-anatomical, and histological features that are highly suggestive of a hereditary neoplastic disease. The details of some of the entities are dealt with in review articles devoted to them in this special issue.
Indexed as
Identifiers
42489911What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.